Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Patients should contact their GP or diabetes team if they experience: Severe, persistent abdominal pain (potential pancreatitis) Persistent vomiting leading to dehydration Signs of hypoglycaemia (if taking alongside insulin or sulphonylureas) Severe or persistent constipation or abdominal distension Right upper quadrant pain, fever or jaundice (potential gallbladder problems) Sudden visual changes (especially in those with diabetic retinopathy) Allergic reactions or injection site problems Weight loss typically becomes noticeable within the first few weeks to months, though the rate varies considerably between individuals
Nevertheless, robust clinical evidence in PsA remains limited, underscoring the need for dedicated randomized controlled trials to clarify the effects of GLP-1RAs on joint inflammation, disease progression, and long-term clinical outcomes
Individual login Institutional login Log in with AGS REGISTER Cookies disabled Cookies are disabled for this browser
A: Some patients report noticeable facial changes while others experience no changes
Patients with and without anti-tesamorelin IgG antibodies had similar mean reductions in visceral adipose tissue (VAT) and IGF-1 response suggesting that the presence of antibodies did not alter the efficacy of tesamorelin
